Contrast-enhanced transrectal ultrasound can reduce collection of unnecessary biopsies when diagnosing prostate cancer and is predictive of biochemical recurrence following a radical prostatectomy in patients with localized prostate cancer

Abstract

Background: To investigate the value of using contrast-enhanced transrectal ultrasound (CETRUS) to reduce unnecessary collection of biopsies during prostate cancer diagnosis and its utility in predicting biochemical recurrence in patients with localized prostate cancer. Methods: This was a prospective study of suspected prostate cancer patients who were evaluated with CETRUS followed by a prostate biopsy. Prostate blood flow via CETRUS was graded using a 5-point scale. The relationship between CETRUS score and biopsy outcome was then analyzed for all patients; univariate and multi-variate analyses were used to determine the probable prognostic factors for biochemical recurrence in patients with localized prostate cancer that underwent a radical prostatectomy. Results: A total of 347 patients were enrolled in the study. Prostate cancer was found in 164 patients. A significant positive correlation (r = 0.69, p < 0.001) was found between CETRUS scores and prostate cancer incidence. Using CETRUS scores ≥2 as the threshold for when to biopsy could have safely reduced the number of biopsies taken overall by 12.1% (42/347) and spared 23.0% (42/183) of patients from undergoing an unnecessary biopsy. 77 patients with localized prostate cancer underwent a radical prostatectomy. The median follow-up time was 30 months (range: 8-56 months) and 17 of these 77 patients exhibited biochemical recurrence during the follow-up period. 3-year biochemical recurrence-free survival rates were 86% for patients with low CETRUS scores (≤ 3) and 59% for patients with high scores (> 3; p = 0.015). Multivariate Cox regression analysis indicated that CETRUS score

Incorporation of trans-rectal color doppler flow imaging and risk-stratification nomogram reduce unnecessary prostate biopsies in suspected prostate cancer patients: a bi-centered retrospective validation study

“…PSAD over 0.15 on the other hand had been adopted in known literatures [ 20 , 21 ] as a predictor of csPCA. Though without wide applications, mSBRS score had shown acceptable preliminary outcomes in predicting the pathological grade of PCA biopsy [ 6 ] as well as the biochemical recurrence [ 22 ]. These combined justified the use of our predictive model as a preliminary risk-stratification tool for csPCA.…”

Contrast-Enhanced Ultrasonography (CEUS) in Imaging of the Reproductive System in Dogs: A Literature Review

“…In human medicine, several papers and reviews have been published on the clinical application of CEUS in the discovery, localization, and assessment of treatment for prostate cancer [3,[59][60][61][62][63][64][65][66][67].…”

The accuracy of prostate cancer diagnosis in biopsy-naive patients using combined magnetic resonance imaging and transrectal ultrasound fusion-targeted prostate biopsy

“…Furthermore, 750,000 men diagnosed with suspicious PCa using the aforementioned screening modalities underwent unnecessary biopsies, with the accompanying pain, inconvenience, financial burden, and risk of infection (14). Therefore, it is necessary to identify and improve alternate methods of diagnosis in patients with positive predictive values so as to avoid unnecessary biopsies (15).…”